Browse News
Filter News
Found 808,146 articles
-
Following cases of convulsions in rabbits in a preclinical study, the FDA has placed a clinical hold on Neumora Therapeutics’ Phase I schizophrenia drug candidate NMRA-266.
-
Roche said Monday that its bispecific T cell engager Columvi improved survival in a Phase III lymphoma trial, clearing the drugmaker to seek a full, expanded label that could drive sales growth.
-
An FDA advisory committee on Friday agreed that using minimal residual disease could be a viable surrogate endpoint for accelerated approval for drug development in multiple myeloma.
-
AbbVie’s small molecule drug Qulipta has durable benefits and can reduce migraine frequency through 48 weeks of follow-up, according to interim Phase III data released on Friday.
-
Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike.
-
Roche’s Genentech subsidiary is terminating for undisclosed reasons its 2021 contract with Adaptimmune for the development of allogeneic T-cell therapeutics.
-
While the VC fund launched on Monday by Regeneron Pharmaceuticals has an investment mandate that includes healthcare broadly, Regeneron Ventures will lean towards biotechnology, devices, tools and enabling technologies.
-
GLP-1 treatments are all the rage in this space, but they aren’t the only approach in development. The pipeline assets highlighted here offer a differentiated approach, potentially increasing efficacy or reducing side effects.
-
Experts are hopeful that objective biomarker measures for amyotrophic lateral sclerosis, such as the ones being developed by EverythingALS, will lead to more targeted, effective treatments.
-
Metabolic dysfunction-associated steatohepatitis experts welcomed Madrigal’s Rezdiffra as an “important first," but there are more mid- to late-stage therapies showing promising results.
-
U.S. Biopharmaceutical CMO & CRO Market Size, Share & Growth Report, 2033
4/15/2024
The U.S. biopharmaceutical CMO & CRO market size was estimated at USD 10.82 billion in 2023 and is projected to hit around USD 19.75 billion by 2033, growing at a CAGR of 6.2% during the forecast period from 2024 to 2033.
-
Biologics Contract Development Market Size to Hit USD 18.68 Bn by 2033 | CAGR 8.2%
4/15/2024
According to Nova One Advisor, the global biologics contract development market size was accounted for USD 8.49 billion in 2023 and it is increasing around USD 18.68 billion by 2033 with a CAGR of 8.2% from 2024 to 2033.
-
U.S. Compounding Pharmacies Market Size, Share, CAGR, Report 2024 to 2033
4/15/2024
According to Vision Research Reports, the U.S. compounding pharmacies market size was estimated at USD 5.79 billion in 2023 and it is expected to increase around USD 10.39 billion by 2033 with a CAGR of 6.02% from 2024 to 2033.
-
Active Pharmaceutical Ingredients Market Size to Increase USD 416.15 Billion By 2033
4/15/2024
The global active pharmaceutical ingredients market size was evaluated at USD 237.48 billion in 2023 and it is expected to increase around USD 416.15 billion by 2033 with a CAGR of 5.77% from 2024 to 2033.
-
Cancer Biomarkers Market Size to Worth Around USD 61.37 Billion by 2033 | CAGR 14.62%
4/15/2024
According to Vision Research Reports, the global cancer biomarkers market size was accounted for USD 15.68 billion in 2023 and it is increasing around USD 61.37 billion by 2033 with a CAGR of 14.62% from 2024 to 2033.
-
Chiesi USA Appoints Richard Smith as Vice President and Business Unit Leader, U.S. AIR
4/15/2024
Chiesi USA, Inc. today announced it has appointed Richard Smith as vice president and business unit leader of U.S. AIR.
-
Pharmacogenomics Market Size is Forecasted to Worth USD 35.67 Billion by 2032
4/15/2024
The global pharmacogenomics market size was reached at USD 15 billion in 2022 and is forecasted to be worth over USD 35.67 billion by 2032 with a CAGR of 9.1% from 2023 to 2032.
-
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)
4/15/2024
CorMedix Inc. today announced DefenCath® (taurolidine and heparin) catheter lock solution (CLS) is now commercially available for U.S. inpatient use.
-
Structural Biology Market Experiencing Rapid Growth
4/15/2024
The global structural biology market is expanding rapidly worldwide, and between 2023 and 2032, hundreds of millions of dollars are expected to be generated in revenue altogether.
-
Robotic Cataract Surgery Using ForSight Robotics’ ORYOMTM Platform Presented For the First Time at the ASCRS Annual Meeting
4/15/2024
Dr. David F. Chang, 2024 Kelman Innovator Lecturer, Presented the Cataract Surgery Robotics Platform at ASCRS Conference